Why the study?
Modest changes in protein glycosylation are associated with clinical heart failure, and aberrant glycosylation in animal models can lead to HF, but its role in adult HFrEF pathogenesis required investigation.
Does deletion of Mgat1 in adult cardiomyocytes cause HFrEF?
Does deletion of Mgat1 in adult cardiomyocytes cause HFrEF?
Deletion of Mgat1 in adult cardiomyocytes causes HFrEF without significant cellular remodeling or fibrosis, highlighting the role of N-glycosylation in heart failure pathogenesis.
Answers are grounded in this paper and cite their sources.
Mgat1 supports adult cardiomyocyte systolic function in mice; leaves open its role in human HFrEF pathogenesis and therapy.
Background Heart failure (HF) presents a massive burden to health care with a complex pathophysiology that results in HF with reduced left ventricle ejection fraction (EF) or HF with preserved EF. It has been shown that relatively modest changes in protein glycosylation, an essential posttranslational modification, are associated with clinical presentations of HF. We and others previously showed that such aberrant protein glycosylation in animal models can lead to HF. Methods and Results We develop and characterize a novel, tamoxifen‐inducible, cardiomyocyte Mgat1 knockout mouse strain, achieved through deletion of Mgat1 , alpha‐1,3‐mannosyl‐glycoproten 2‐beta‐N‐acetlyglucosaminyltransferase, which encodes N‐acetylglucosaminyltransferase I. We investigate the role of hybrid/complex N‐glycosylation in adult HFrEF pathogenesis at the ion channel, cardiomyocyte, tissue, and gross cardiac level. The data demonstrate successful reduction of N‐acetylglucosaminyltransferase I activity and confirm that hybrid/complex N‐glycans modulate gating of cardiomyocyte voltage‐gated calcium channels. A longitudinal study shows that the tamoxifen‐inducible, cardiomyocyte Mgat1 knockout mice present with significantly reduced systolic function by 28 days post induction that progresses into HFrEF by 8 weeks post induction, without significant ventricular dilation or hypertrophy. Further, there was minimal, if any, physiologic or pathophysiologic cardiomyocyte electromechanical remodeling or fibrosis observed before (10–21 days post induction) or after (90–130 days post induction) HFrEF development. Conclusions The tamoxifen‐inducible, cardiomyocyte Mgat1 knockout mouse strain created and characterized here provides a model to describe novel mechanisms and causes responsible for HFrEF onset in the adult, likely occurring primarily through tissue‐level reductions in electromechanical activity in the absence of (or at least before) cardiomyocyte remodeling and fibrosis.
No takes yet. Share an insight, caveat, or question.
Young et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: